Skip to main content
Premium Trial:

Request an Annual Quote

Celera Posts Q2 Profit; Revenues Rise on Acquisitions

NEW YORK (GenomeWeb News) – Celera today posted a second-quarter profit of $300,000, or $.00 per share, its first ever quarterly profit. For last year’s fiscal second quarter the firm had posted a net loss of $500,000, or $.01 per share.
Celera’s revenues rose more than 200 percent to $40.3 million from $13.2 million year over year. However, this year’s Q2 results include revenue contributions from Berkeley HeartLab and Atria Genetics, which the firm acquired a few months ago. Excluding revenues from those firms, Celera’s sales rose 26.5 percent to $16.7 million.
The firm’s R&D costs declined 11.7 percent to $10.6 million from $12 million. Its SG&A costs rose sharply, nearly tripling to $20.1 million from $7.3 million last year.
The $195 million acquisition of Berkeley HeartLab in October provided Celera with technologies to develop new predictive molecular diagnostics for cardiovascular disease. Celera also gained a direct marketing vehicle for its tests and a CLIA lab through the purchase.
The firm also paid $33 million that month to acquire Atria Genetics, a maker of human leukocyte antigen-testing products used in organ donor matching.
“With the acquisition of Berkeley HeartLab, Celera now has greater scale and diversity, a commercial infrastructure to develop the market for tests that incorporate our proprietary discoveries, and a comprehensive platform for cardiovascular disease management,” Tony White, chairman of Celera parent firm Applera, said in a statement. “These advances in the business support the Applera board's preference to prepare Celera for separation from Applera by the end of fiscal 2008.”
As reported by GenomeWeb Daily News earlier this month, Celera President Kathy Ordoñez told investors at the JPMorgan Healthcare Conference that Applera’s board of directors recently stated its preference that the affiliated firms be split into two independent entities rather than remaining tracking stocks of Applera.
Celera expects to report fiscal 2008 revenues in a range between $135 million and $145 million.

The Scan

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.

US Survey Data Suggests Ancestry Testing Leads Way in Awareness, Use of Genetic Testing Awareness

Although roughly three-quarters of surveyed individuals in a Genetics in Medicine study reported awareness of genetic testing, use of such tests was lower and varied with income, ancestry, and disease history.

Coral Genome Leads to Alternative Amino Acid Pathway Found in Other Non-Model Animals

An alternative cysteine biosynthesis pathway unearthed in the Acropora loripes genome subsequently turned up in sequences from non-mammalian, -nematode, or -arthropod animals, researchers report in Science Advances.

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.